Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street

Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts. Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That comp...

By Tyler Durden